PHARMAC is seeking feedback on a proposal relating to the funding of the TNF-inhibitor medicines adalimumab (Humira) and etanercept (Enbrel), both used to treat people with various autoimmune and immune-mediated conditions, and gabapentin (Neurontin), used to treat epilepsy and neuropathic pain.

The effect of the proposal would be to make the funding of the TNF-inhibitor treatments and Neurontin more cost-effective and to create savings of more than $20 million over 5 years that would enable PHARMAC to deliver greater health outcomes from available pharmaceutical funding.

PHARMAC welcomes feedback on this proposal by 5pm on Tuesday, 11 August 2015.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2015-07-14-tnf-inhibitors/